Essential role of kidney biopsy in diagnosing glomerular diseases amidst evolving biomarkers

doi:10.5527/wjn.v14.i2.103756

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (378)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series.

Item

Count

PDF

HTML

167

Figures (1-2)

Sum=211

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=128

Publishing Process of This Article

Item

Count

Browse

Download

Sum=26

Jun 25, 2025 (publication date) through Apr 18, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Nephrol. Jun 25, 2025; 14(2): 103756
Published online Jun 25, 2025. doi: 10.5527/wjn.v14.i2.103756

Essential role of kidney biopsy in diagnosing glomerular diseases amidst evolving biomarkers

Fernando M Gonzalez, Ricardo Valjalo

Fernando M Gonzalez, Department of Nephrology, Faculty of Medicine, Universidad de Chile, Santiago 7500922, Chile

Ricardo Valjalo, Department of Nephrology, Hospital del Salvador, Santiago 7500922, Región Metropolitana, Chile

Co-first authors: Fernando M Gonzalez and Ricardo Valjalo.

Author contributions: Gonzalez FM and Valjalo R contributed to the discussion, writing, literature review, and manuscript design.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Fernando M Gonzalez, MD, Professor, Department of Nephrology, Faculty of Medicine, Universidad de Chile, Avenida Salvador 486, Providencia, Santiago 7500922, Chile. fgonzalf@uc.cl

Received: November 29, 2024
Revised: February 23, 2025
Accepted: March 5, 2025
Published online: June 25, 2025
Processing time: 131 Days and 13.1 Hours

Core Tip

Core Tip: Puspitasari et al reported significant changes in biopsy indications and histological outcomes before and after the coronavirus disease 2019 (COVID-19) pandemic, reflecting the interconnectedness of clinical practices, public health challenges, and patient demographics. Nevertheless, the COVID-19 pandemic has revealed vulnerabilities in nephrology services, necessitating flexible management strategies for chronic conditions.